DRD2 and schizophrenia: Of interest, the use of antipsychotics with predominant dopamine D3 receptor (D3R) antagonism, which are less prone to induce sensitization, or compounds that minimize postsynaptic D2R blockade by acting preferentially at other sites or at a presynaptic level, has recently been explored as a strategy to treat schizophrenia while preventing secondary resistance by avoiding postsynaptic D2R upregulation [27,28,29].